Document is current
Any future updates will be listed below
-
Authors
Balmaña, Judith https://orcid.org/0000-0002-0762-6415
Fasching, Peter A. https://orcid.org/0000-0003-4885-8471
Couch, Fergus J. https://orcid.org/0000-0001-9417-9985
Delaloge, Suzette https://orcid.org/0000-0003-2106-9165
Labidi-Galy, Intidhar https://orcid.org/0000-0002-0824-3475
O’Shaughnessy, Joyce
Park, Yeon Hee
Eisen, Andrea F. https://orcid.org/0000-0001-8037-9556
You, Benoit https://orcid.org/0000-0002-3177-8857
Bourgeois, Hughes
Gonçalves, Anthony https://orcid.org/0000-0001-7570-7439
Kemp, Zoe
Swampillai, Angela https://orcid.org/0000-0003-1984-3633
Jankowski, Tomasz https://orcid.org/0000-0002-0049-7673
Sohn, Joo Hyuk https://orcid.org/0000-0002-2303-2764
Poddubskaya, Elena https://orcid.org/0000-0001-6476-6337
Mukhametshina, Guzel
Aksoy, Sercan https://orcid.org/0000-0003-4984-1049
Timcheva, Constanta V. https://orcid.org/0000-0002-4245-7864
Park-Simon, Tjoung-Won
Antón-Torres, Antonio https://orcid.org/0000-0002-9159-4988
John, Ellie
Baria, Katherine
Gibson, Isabel
Gelmon, Karen A. https://orcid.org/0000-0003-4111-2757
,
,
Koynova, Tatyana
Popov, Vasil
Timcheva, Constanta
Tomova, Antoaneta
,
Eisen, Andrea
Gelmon, Karen
Lemieux, Julie
,
Augereau, Paule
Bazan, Fernando
Becuwe, Célia
Bourgeois, Hugues
Chakiba, Camille
Chehimi, Mohamad
Cheneau, Caroline
Dalenc, Florence
de Guillebon, Eléonore
de La Motte Rouge, Thibault
Frenel, Jean-Sébastien
Gonçalves, Anthony
Grenier, Julien
Hardy-Bessard, Anne Claire
Lamy, Regine
Levy, Christelle
Lortholary, Alain
Mailliez, Audrey
Medioni, Jacques
Patsouris, Anne
Spaeth, Dominique
Teixeira, Luis
Tennevet, Isabelle
Venat-Bouvet, Laurence
Villanueva, Cristian
You, Benoit
,
Ettl, Johannes
Fasching, Peter
Gerber, Bernd
Hanusch, Claus Alexander
Hoffmann, Oliver
Park-Simon, Tjoung-Won
Malter, Wolfram
Reinisch, Mattea
Tio, Joke
Wimberger, Pauline
,
Boer, Katalin
Dank, Magdolna
,
Ballestrero, Alberto
Bianchini, Giampaolo
Biganzoli, Laura
Bordonaro, Roberto
Cognetti, Francesco
Cortesi, Enrico
De Laurentiis, Michelino
De Placido, Sabino
Gianni, Luca
Guarneri, Valentina
Marchetti, Paulo
Montemurro, Filippo
Mosconi, Anna Maria
Naso, Giuseppe
Puglisi, Fabio
Santoro, Armando
Zamagni, Claudio
,
Iwata, Hiroji
Kim, Seung-Jin
Nakamura, Seigo
,
Chae, Yee Soo
Cho, Eun Kyung
Kim, Jee Hyun
Im, Seock-Ah
Lee, Keun Seok
Park, Yeon Hee
Sohn, Joo Hyuk
,
Byrski, Tomasz
Huzarski, Tomasz
Jankowski, Tomasz
Kukielka-Budny, Bozena
Lacko, Aleksandra
Nowecki, Zbigniew
Senkus-Konefka, Elzbieta
Szoszkiewicz, Renata
Tarnawski, Rafal
,
Andabekov, Timur
Dvorkin, Mikhail
Dvornichenko, Viktoria
Moiseenko, Fedor
Mukhametshina, Guzel
Poddubskaya, Elena
Popova, Ekaterina
Tarasova, Anna
Sakaeva, Dina
Shomova, Marina
Vats, Anna
,
Adamo, Bárbara
Conejero, Raquel Andrés
Torres, Antonio Antón
Gelpi, Judith Balmaña
de Ibarguen, Blanca Cantos Sánchez
Jurado, Josefina Cruz
Fernández, Nieves Díaz
González, Alejandro Falcón
Garcia, Juan
Santiago, Santiago González
Carrasco, Fernando Henao
Lorenzo, Isabel Lorenzo
Antón, Fernando Moreno
García, Beatriz Rojas
Beltrán, Salomón Menjón
Santisteban, Marta
Stradella, Agostina
,
Hou, Ming-Feng
Huang, Chiun-Sheng
Lin, Yung-Chang
Tseng, Ling-Ming
Wang, Hwei-Chung
,
Aksoy, Sercan
Arslan, Cagatay
Artac, Mehmet
Aydiner, Adnan
Disel, Umut
Ozkan, Metin
Ozyilkan, Ozgur
Sezer, Emel Yaman
Yetisyigit, Tarkan
,
Armstrong, Anne
Barrett, Sophie
Borley, Annabel
Kemp, Zoe
Michie, Caroline
Mukesh, Mukesh
Perren, Timothy
Swampillai, Angela
,
Chaudhry, Madhu
Young, Tammy
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03286842 at ClinicalTrials.govDocuments that mention this clinical trial
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
https://doi.org/10.1007/s10549-023-07165-x
-
Funding
Funding for this research was provided by:
AstraZeneca
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
- License Information
-
More Information
Article History
Received: 14 July 2023
Accepted: 23 October 2023
First Online: 19 December 2023
Declarations
:
: The following authors have received compensation for serving as a consultant, invited speaker, or medical writer, or they or the institutions they work for have received research support from the companies or organizations indicated: J Balmaña (AstraZeneca, PharmaMar, and Pfizer); PA Fasching (Agendia, Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Eli Lilly, Hexal, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Roche, and Seagen); FJ Couch (Ambry Genetics, AstraZeneca, GRAIL, Qiagen, and US Oncology); S Delaloge (AstraZeneca, Besins Healthcare, Bristol Myers Squibb, Cellectis, Eli Lilly, Exact Sciences, GE, Novartis, Orion, Pfizer, Pierre Fabre, Puma Biotechnology, Rappta Therapeutics, Roche Genentech, Sanofi, Seagen, Servier, and Taiho Pharma); I Labidi-Galy (AstraZeneca and PharmaMar); J O’Shaughnessy (AbbVie, Agendia, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Eisai, Genentech, Genomic Health, GRAIL, HERON, Immunomedics, Ipsen, Jounce Therapeutics, Lilly, Merck Sharp & Dohme, Myriad Pharmaceuticals, Novartis, Odonate Therapeutics, Pfizer, Puma Biotechnology, Roche, Samsung, Sanofi, Seattle Genetics, and Syndax); YH Park (AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme, Novartis, Pfizer, and Roche); B You (AstraZeneca); H Bourgeois (Daiichi Sankyo, Lilly, and Novartis); A Goncalves (AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Merck Sharp & Dohme, Novartis, Roche, Sanofi, and Seagen); Z Kemp (AstraZeneca and Lilly); JH Sohn (AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Sanofi); S Aksoy (AstraZeneca, Bristol Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, and Roche); CV Timcheva (AstraZeneca, Eli Lilly, i3 Research, Merck Sharp & Dohme, Novartis, Parexel, and Roche); T-W Park-Simon (AstraZeneca, Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Seagen); A Antón-Torres (AstraZeneca, Eli Lilly, Daichi Sankyo, Gilead, Roche, and Seagen); KA Gelmon (AstraZeneca, Ayala, Bristol Myers Squibb, Eli Lilly, Gilead Sciences, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Seagen). E John, K Baria, and I Gibson are employees and/or stockholders of AstraZeneca. T Jankowski, G Mukhametshina, E Poddubskaya, AF Eisen, and A Swampillai have declared no conflicts of interest.
: The trial was performed in accordance with the Declaration of Helsinki, International Conference on Harmonisation of Good Clinical Practice guidelines, applicable regulatory requirements, and the AstraZeneca Global Standard on Bioethics []. The trial protocol was approved by independent ethics review committees at all participating institutions/countries.
: All patients provided written informed consent to participate.
: All patients provided written informed consent to publish.
